Research guide / MOTS-c
What is MOTS-c? A Complete Research Guide.
Updated August 2026 · 9 minute read
MOTS-c is a 16-amino-acid peptide encoded in the mitochondrial genome, studied for its role in metabolism and exercise biology. This guide separates the published cell, mouse, and human-exercise research from what regulators have actually said.
01 / Overview
What is MOTS-c?
MOTS-c (mitochondrial open reading frame of the 12S rRNA-c) is a 16-amino-acid peptide encoded by a short open reading frame within the mitochondrial 12S rRNA gene. It was identified in 2015 by Lee, Cohen, and colleagues at the University of Southern California as a signalling molecule that regulates insulin sensitivity and metabolic homeostasis — one of a small class of 'mitochondrial-derived peptides' that also includes humanin.[1]
Unlike most research peptides, MOTS-c is a molecule the human body makes naturally. Circulating MOTS-c levels have been measured in people and shown to respond to exercise, which is why it is often described as an 'exercise-induced' or 'exercise-mimetic' signal in the research literature.[2]
The critical context: almost everything known about MOTS-c's effects comes from cell cultures and mice. There are no completed human clinical trials of MOTS-c administration, no registered drug development programme, and no approved product anywhere. Human data so far consists of observational measurements of the body's own MOTS-c — not of giving it to people.
02 / Mechanism
How does MOTS-c work?
The discovery paper mapped a specific pathway: MOTS-c targets skeletal muscle, inhibits the folate cycle and its tethered de novo purine biosynthesis, raises levels of the metabolite AICAR, and thereby activates AMPK — a central cellular energy sensor also activated by exercise and by the drug metformin.[1], [3]
| Aspect | What research reports | Research relevance |
|---|---|---|
| AMPK activation | MOTS-c inhibits the folate–purine pathway, raising AICAR and activating AMPK in muscle cells. | AMPK is a master energy sensor; the proposed core metabolic mechanism. |
| Skeletal muscle targeting | Muscle appears to be the primary target organ in animal studies. | Frames the exercise-biology research interest. |
| Exercise response | Circulating MOTS-c rises after exercise in humans; muscle levels decline with age. | The basis for 'exercise-mimetic' framing — an association, not an administered-drug result. |
This pathway was characterised in cell and mouse systems. AMPK activation is a well-validated metabolic mechanism in general, but whether administered MOTS-c produces meaningful metabolic effects in humans has never been tested in a clinical trial.
03 / Published evidence
Peer-reviewed findings
Lee et al. 2015 (Cell Metabolism) reported that MOTS-c treatment in mice prevented age-dependent and high-fat-diet-induced insulin resistance and diet-induced obesity, with skeletal muscle as its primary target organ. These were animal findings; no humans were treated.[1]
Reynolds et al. 2021 (Nature Communications) added the human observational layer: circulating MOTS-c levels rose with exercise in people, and levels in muscle declined with age. In the same paper, MOTS-c treatment improved exercise capacity in old mice.[2]
That 2021 paper is frequently cited as 'human evidence' for MOTS-c. Read precisely, the human data show the body's own MOTS-c responds to exercise — an association. The intervention results (improved performance) were in mice. No study has administered MOTS-c to humans and measured an outcome.[2]
Review literature places MOTS-c within the broader mitochondrial-derived peptide family and proposes roles in muscle and fat metabolism, stress response, and ageing biology. These are synthesis papers organising the preclinical evidence, not new human data.[3]
04 / Evidence landscape
How the evidence is structured
MOTS-c has no completed or ongoing registered clinical trial programme of administered peptide. The table below maps the full published evidence base.
| Category | Example | Scale | What it can show |
|---|---|---|---|
| Cell studies | Lee et al., 2015 | Cultured cells | Pathway mapping (folate–purine–AMPK) |
| Mouse studies | Lee et al., 2015; Reynolds et al., 2021 | Rodent models | Insulin sensitivity, diet-induced obesity, exercise capacity in mice |
| Human observational data | Reynolds et al., 2021 | Measured volunteers | The body's own MOTS-c responds to exercise; no administered dosing |
| Human clinical trials | None exist | — | No human efficacy or safety data of any kind |
This mapping reflects the published records reviewed for this August 2026 update. The pattern to notice: the further down the table, the less direct the evidence — and no row involves giving MOTS-c to humans.[1], [2]
Afiya Labs lists a MOTS-c reference material for laboratory research. The catalogue entry is not a medicine listing and is not presented as suitable for human use.
05 / Safety evidence
What safety evidence exists?
No human safety studies of administered MOTS-c exist. The published intervention work is in mice, which cannot establish a human safety profile. Observational studies of the body's own MOTS-c levels say nothing about the safety of injecting it.[1], [2]
The U.S. FDA has placed MOTS-c in Category 2 of its interim compounding policy — bulk substances identified as potentially presenting significant safety risks in compounding. Category placement is a regulatory risk signal, not a full safety assessment, and it concerns compounded products.[4]
Anyone reading claims about MOTS-c use should weigh them against the total absence of controlled human data — for efficacy and for safety alike.
06 / Regulators
Status in the US, Europe, and UAE
United States
MOTS-c is not an FDA-approved drug. Under the FDA's interim compounding policy, MOTS-c appears in Category 2 — bulk substances that may present significant safety risks in compounding. This category concerns pharmacy compounding and is not a marketing authorisation.[4]
European Union
MOTS-c is not authorised as a medicine in the EU and has no pharmaceutical development programme in any jurisdiction.
United Arab Emirates
The Emirates Drug Establishment maintains the UAE's public registered medical product directory. We did not rely on a directory search to infer approval, non-approval, legality, availability, or permission for use of any specific product; those questions require confirmation from the EDE. Approved medicines in the UAE are dispensed through licensed channels.[5]
07 / Quick answers
Frequently asked questions
Is MOTS-c an approved medicine?
No. MOTS-c is not approved as a drug in the US, authorised as a medicine in the EU, or approved anywhere else. No clinical development programme exists.
Is MOTS-c natural?
Yes — unusually for a research peptide, MOTS-c is encoded in the human mitochondrial genome and produced by the body. Research materials are synthetically produced copies of the natural sequence.
Is MOTS-c really an 'exercise pill'?
That framing overstates the evidence. Human data show the body's own MOTS-c rises with exercise. The performance improvements seen with MOTS-c treatment were in mice. No trial has given MOTS-c to humans and measured exercise or metabolic outcomes.
What does the research actually show?
A well-characterised mechanism in cells (folate–purine–AMPK), metabolic and exercise-capacity effects in mice, and observational human data linking natural MOTS-c levels to exercise and age. Nothing in humans administered the peptide.
How is MOTS-c different from other metabolic peptides?
It is encoded in mitochondrial DNA rather than nuclear DNA, and it acts through AMPK — a different pathway from incretin-based medicines like semaglutide or tirzepatide, which have full human trial programmes.
What does the UAE directory show?
It is a public register of medical products. This guide does not turn a directory search result — or the absence of one — into a claim about approval, legality, or permitted use. The EDE is the appropriate authority for a current determination.
08 / Sources
References and original records
- 1The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism (Lee et al., University of Southern California). 2015 · DOI 10.1016/j.cmet.2015.02.009 · The discovery paper; cell and mouse studies.
- 2MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nature Communications (Reynolds et al.). 2021 · DOI 10.1038/s41467-020-20790-0 · Human exercise measurements plus mouse intervention data.
- 3MOTS-c: a novel mitochondrial-derived peptide regulating muscle and fat metabolism. Free Radical Biology and Medicine (Kim et al.). 2018 · DOI 10.1016/j.freeradbiomed.2018.05.015 · Peer-reviewed review.
- 4Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (Category 2). U.S. Food and Drug Administration. Official regulatory list · includes MOTS-c.
- 5Registered medical product directory. UAE Emirates Drug Establishment. Official public directory · checked August 2026.